|
|
|
|
|
IAS 18 |
|
IFRS 15 |
IFRS 15 |
IAS 18 |
IAS 18 |
IFRS 15 |
||
|
Agreement |
Consideration |
Consideration |
Collaboration start date |
Outstanding balance in deferred income as at 31 December 2017 |
Deferred income reclassified from equity following adoption of IFRS 15 |
Outstanding balance in deferred income as at 1 January 2018 |
Revenue recognized, six months ended 30 June 2018 |
Revenue recognized, six months ended 30 June 2018 |
Revenue recognized, six months ended 30 June 2017 |
Outstanding balance in deferred income as at 30 June 2018 |
||
|
|
(thousands of $) |
(thousands of €) |
|
(thousands of €) |
||||||||
|
||||||||||||
|
Revenue recognition of considerations received prior to 31 December 2017 |
||||||||||||
|
Gilead collaboration agreement for filgotinib – Upfront payment |
300,000 |
275,558 |
January 2016 |
187,449 |
– |
187,449 |
43,215 |
43,215 |
27,114 |
144,234 |
||
|
Gilead collaboration agreement for filgotinib – Subscription agreement(*) |
N.A. |
39,003 |
January 2016 |
26,532 |
– |
26,532 |
6,116 |
6,116 |
3,838 |
20,416 |
||
|
Servier collaboration agreement for osteoarthritis – License fee |
N.A. |
6,000 |
June 2010 |
5,362 |
(5,362) |
– |
– |
766 |
– |
– |
||
|
AbbVie collaboration agreement for CF – Upfront payments |
45,000 |
34,001 |
September 2013 |
– |
14,872 |
14,872 |
3,422 |
– |
– |
11,450 |
||
|
Total upfront and license fees: |
|
219,343 |
9,510 |
228,853 |
52,753 |
50,097 |
30,952 |
176,099 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Gilead collaboration agreement for filgotinib – Milestone payments |
70,000 |
64,435 |
January 2016 |
– |
43,832 |
43,832 |
10,105 |
– |
9,354 |
33,727 |
||
|
AbbVie collaboration agreement for CF – Milestone payments |
77,500 |
68,310 |
September 2013 |
– |
29,878 |
29,878 |
6,875 |
– |
16,566 |
23,003 |
||
|
Total milestones: |
|
|
– |
73,710 |
73,710 |
16,980 |
– |
25,920 |
56,730 |
|||
|
Total: |
|
|
219,343 |
83,220 |
302,563 |
69,734 |
50,097 |
56,872 |
232,829 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Revenue recognition of considerations in the six months ended 30 June 2018 |
||||||||||||
|
Gilead collaboration agreement for filgotinib – Milestone payments |
15,000 |
12,418 |
January 2016 |
– |
– |
– |
5,918 |
12,418 |
– |
6,500 |
||
|
AbbVie collaboration agreement for CF – Milestone payments |
10,000 |
8,548 |
September 2013 |
– |
– |
– |
5,669 |
8,548 |
– |
2,879 |
||
|
Total milestones: |
|
|
– |
– |
– |
11,587 |
20,966 |
– |
9,379 |
|||
|
Grand total: |
|
|
219,343 |
83,220 |
302,563 |
81,321 |
71,063 |
56,872 |
242,208 |
|||